Antibody-Drug Conjugates SOT110

SOT110 broadens SOTIO’s pipeline of next-generation ADCs to address the challenges of solid tumors. SOT110 is currently in preclinical development stage against an undisclosed target. With three different platform technologies available (NBE-Therapeutics, LegoChem, Synaffix), the purpose is to select and tailor the most suitable ADC technology and payload for the needs of this particular target in particular solid tumor indications.